PBR Nachrichten

 

The decision marks the third NMPA-approved indication for an ivonescimab-containing regimen in the country since the molecule first received authorisation in May 2024. Ivonescimab is described as an The post Akeso secures China NMPA authorisation for ivonescimab combo appeared first on Pharmaceutical Business review....

The proceeds will also be used to fund Remepy's lead product Hybridopa's global Phase III clinical trial targeting Parkinson's disease (PD). It is set to commence in the The post Remepy secures $36m funding for hybrid drug pipeline expansion appeared first on Pharmaceutical Business review....

The arrangement enables Sentynl to acquire exclusive US commercial rights to alvelestat upon exercise of the option while Mereo BioPharma will retain commercial rights outside the US. Under The post Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat appeared first on Pharmaceutical Business review....

The transaction is structured through a share purchase agreement with SEVER Life Sciences for 100% of Nordic Group and its subsidiaries. While specific financial terms have not been The post Alfasigma signs agreement to acquire Nordic Group appeared first on Pharmaceutical Business review....

The deal includes joint studies combining BeOne's cancer pipeline assets with four clinical-stage RAS(ON) inhibitors from Revolution Medicines, alongside a regional rights agreement for select Asian markets. The The post BeOne and Revolution Medicines partner for oncology therapies appeared first on Pharmaceutical Business review....

Unanimously approved by both companies' boards, the transaction is expected to close by the fourth quarter (Q4) of 2026, pending customary closing conditions. Jazz Pharmaceuticals plans to fund The post Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront appeared first on Pharmaceutical Business review....

Under the contract, Daiichi Sankyo will continue to handle development, manufacturing, and supply of the therapy while Innovent Biologics will lead market promotion and commercialisation activities in China. The post Innovent and Daiichi Sankyo sign deal for Vanflyta in China appeared first on Pharmaceutical Business review....

The collaboration will focus on process technology transfer and activities relating to chemistry, manufacturing and controls (CMC) to support a possible new drug application (NDA) in Taiwan for The post Energenesis and Taiwan Tanabe to develop ENERGI-F703DFU for DFUs appeared first on Pharmaceutical Business review....

These conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation. Ono will work alongside Mediar to utilise its fibrosis-focused discovery platform, expertise in The post Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments appeared first on Pharmaceutical Business review....

This collaboration will focus on utilising Evotec's data-driven discovery platform alongside its AI data science and advanced screening technologies. It aims to accelerate the discovery and validation of The post Evotec and Odyssey collaborate on AI-enabled R&D appeared first on Pharmaceutical Business review....

The agreement involves access to ALT-B4 (berahyaluronidase alfa), a recombinant human hyaluronidase created with Alteogen's Hybrozyme platform. This technology is intended to convert biologics typically given via intravenous The post Alteogen signs $365m Hybrozyme licensing deal with pharma company appeared first on Pharmaceutical Business review....

This initiative builds on an established partnership between the two companies, under which BMS already utilises Schrödinger's computational platform for drug discovery projects. The new arrangement will extend The post Schrödinger and BMS expand partnership to deploy AI for drug discovery appeared first on Pharmaceutical Business review....

The funds will be used for AsymBio's principal business operations and drive further expansion of its manufacturing capacity. Asymchem Group will contribute 1.05bn yuan while Hillhouse Qirui will The post AsymBio to secure $184m to support growth in biologics manufacturing appeared first on Pharmaceutical Business review....

The move aims to address challenges in the sector where analytical work behind research decisions is often slow and dispersed, pushing scientists to use multiple disconnected tools and The post Phylo and Chugai collaborate to deploy AI platform in drug discovery appeared first on Pharmaceutical Business review....

The designation is specifically for patients whose tumours demonstrate a KRAS G12C mutation confirmed by an FDA-approved test and covers olomorasib administered as a monotherapy. Olomorasib (LY3537982) is The post FDA grants breakthrough therapy designation to Lilly's olomorasib appeared first on Pharmaceutical Business review....

The deal will take the Nasdaq-listed Lantheus private. Under the agreement, Curium US will purchase all outstanding shares of Lantheus for $102.50 per share upon closing. Lantheus' shareholders The post Curium to acquire Lantheus in all-cash deal worth up to $8bn appeared first on Pharmaceutical Business review....

The agreement covers the use of senaparib as a maintenance monotherapy for adult patients with advanced epithelial high-grade ovarian, fallopian tube, and primary peritoneal cancer. Under the agreement, The post IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib appeared first on Pharmaceutical Business review....

The company said existing investors Duquesne Family Office and Bristol Myers Squibb participated in the round, joined by new investors Catalio Capital Management, Eli Lilly and Company, and The post Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy appeared first on Pharmaceutical Business review....

The partnership is intended to jointly advance methods that address one of the main challenges for RNA medicines: delivering treatments to additional tissue types. While existing RNA therapies The post miRecule and Rio Biofarma to develop RNA therapeutic delivery technologies appeared first on Pharmaceutical Business review....

The investment will support the expansion of Resilience's advanced manufacturing operations in the Cincinnati region and create at least 400 new jobs. With this initiative, the total number The post Resilience and Lilly to increase US medicines production with $750m investment appeared first on Pharmaceutical Business review....